scholarly journals Undiagnosed Behçet’s Disease Presenting as Fournier’s Gangrene in a Young Male

2021 ◽  
Vol 2021 ◽  
pp. 1-2
Author(s):  
Jasmine C. Winyard ◽  
Anton Wong ◽  
Hala Rashed ◽  
John K. Mellon
Keyword(s):  
Risk Factors ◽  
Behçet’S Disease ◽  
Behcet’S Disease ◽  
Behçet's Disease ◽  
Case Reports ◽  
Young Male ◽  
Paediatric Population ◽  
Fournier’S Gangrene ◽  
Fournier's Gangrene ◽  
Behcet's Disease

Behçet’s disease is rare, especially in the paediatric population. In this case, a healthy 16-year-old made presented with discrete scrotal ulcers and systemic illness. He was found to have Fournier’s gangrene and with subsequent investigation was diagnosed with Behçet’s disease as an underlying cause. A PubMed search reveals no similar case reports. His only risk factors for Fournier’s gangrene was his raised body mass index. His only risk factor for Behçet’s disease was his ethnic origin. An understanding of risk factors and epidemiology can raise suspicion of these rare pathologies.

scholarly journals Behcet’s Disease with Intracardiac Thrombus Presenting with Fever of Unknown Etiology

2015 ◽  
Vol 2015 ◽  
pp. 1-3
Author(s):  
Sajal Ajmani ◽  
Durga Prasanna Misra ◽  
Deep Chandh Raja ◽  
Namita Mohindra ◽  
Vikas Agarwal
Keyword(s):  
Behçet’S Disease ◽  
Behcet’S Disease ◽  
Behçet's Disease ◽  
Thrombus Formation ◽  
Young Male ◽  
Unknown Etiology ◽  
High Dose ◽  
Intracardiac Thrombus ◽  
High Grade Fever ◽  
Behcet's Disease

A young male was referred to us for evaluation of fever of unknown origin (FUO). He had history of recurrent painful oral ulcers for one year and moderate to high grade fever, pustulopapular rash, and recurrent genital ulcers for 6 months and hemoptysis for 3 days. He was detected to have intracardiac thrombi and pulmonary arterial thrombosis along with underlying Behcet’s disease (BD). Patient responded to high dose prednisolone (1 mg/Kg/day) along with monthly parenteral cyclophosphamide therapy. This case highlights the fact that BD is an important cause for pulmonary artery vasculitis with intracardiac thrombus formation, and such patients can present with FUO.

scholarly journals Off-Label Uses of Anti-TNF Therapy in Three Frequent Disorders: Behçet’s Disease, Sarcoidosis, and Noninfectious Uveitis

2013 ◽  
Vol 2013 ◽  
pp. 1-10 ◽  
Author(s):  
Daniel Sánchez-Cano ◽  
José Luis Callejas-Rubio ◽  
Ricardo Ruiz-Villaverde ◽  
Raquel Ríos-Fernández ◽  
Norberto Ortego-Centeno
Keyword(s):  
Behçet’S Disease ◽  
Behcet’S Disease ◽  
Behçet's Disease ◽  
Case Reports ◽  
Certolizumab Pegol ◽  
Case Series ◽  
Behcet's Disease ◽  
Off Label ◽  
Inflammatory Bowel ◽  
Necrosis Factor

Tumoral necrosis factorαplays a central role in both the inflammatory response and that of the immune system. Thus, its blockade with the so-called anti-TNF agents (infliximab, etanercept, adalimumab, certolizumab pegol, and golimumab) has turned into the most important tool in the management of a variety of disorders, such as rheumatoid arthritis, spondyloarthropatties, inflammatory bowel disease, and psoriasis. Nonetheless, theoretically, some other autoimmune disorders may benefit from these agents. Our aim is to review these off-label uses of anti-TNF blockers in three common conditions: Behçet’s disease, sarcoidosis, and noninfectious uveitis. Due to the insufficient number of adequate clinical trials and consequently to their lower prevalence compared to other immune disorders, this review is mainly based on case reports and case series.

Protein C and Protein S activities in Behçet's disease as risk factors of thrombosis

1998 ◽  
Vol 37 (2) ◽  
pp. 124-125 ◽  
Author(s):  
Nurdan Lenk, MD ◽  
Gülsüm Özet, MD ◽  
Nuran Alli, MD ◽  
Özgül Çoban, MD ◽  
Servet Erbaşi, MD
Keyword(s):  
Risk Factors ◽  
Behçet’S Disease ◽  
Protein C ◽  
Behcet’S Disease ◽  
Behçet's Disease ◽  
Protein S ◽  
Behcet's Disease

Behçet’s disease and comorbidity: internal case reports and literature review

2015 ◽  
Vol 35 (10) ◽  
pp. 1743-1747 ◽  
Author(s):  
Zemfira Alekberova ◽  
Vadim Gorodetskiy ◽  
Fatima Izmailova ◽  
Stefka Radenska-Lopovok ◽  
Elnura Talybova ◽  
...  
Keyword(s):  
Literature Review ◽  
Behçet’S Disease ◽  
Behcet’S Disease ◽  
Behçet's Disease ◽  
Case Reports ◽  
Behcet's Disease

scholarly journals Neuro-Behçet’s Disease – Clinical Features, Diagnosis and Differential Diagnosis

2018 ◽  
Vol 13 (2) ◽  
pp. 93
Author(s):  
Selen Ozyurt ◽  
Petros Sfikakis ◽  
Aksel Siva ◽  
Cris S Constantinescu ◽  
◽  
...  
Keyword(s):  
Differential Diagnosis ◽  
Behçet’S Disease ◽  
Behcet’S Disease ◽  
Behçet's Disease ◽  
Case Reports ◽  
Illustrative Case ◽  
Inflammatory Disorder ◽  
Behcet's Disease ◽  
Multisystem Involvement ◽  
The Central Nervous System

Background:Behçet’s disease is a relatively uncommon, inflammatory disorder with characteristic mucocutaneous lesions and multisystem involvement, of unknown aetiology; presumably a vascular autoinflammatory syndrome that develops under combined environmental and genetic influences. As neuro-Behçet’s disease affects the central nervous system in about 10% of cases and in ways that can mimic other neuroinflammatory conditions, awareness of its manifestations, significance, and management is important for neurologists. In March 2017, a mini-symposium at the 11th Congress of Controversies in Neurology in Athens, Greece, was dedicated to specific aspects of Behçet’s and neuro-Behçet’s disease. These included an introduction to Behçet’s disease, pathogenesis and treatment, an overview of its neurological manifestations (neuro-Behçet’s disease) and the differential diagnosis from other neuroinflammatory conditions. Illustrative case reports were used.Objectives:To provide a brief overview of neuro-Behçet’s disease that is informative for clinical neurological practice and that follows the structure of the 2017 mini-symposium.Data sources:Relevant recent comprehensive reviews of the subject and relevant original articles and case reports were provided by each speaker at the mini-symposium. This article contains some of these sources and some additions where necessary to emphasise specific points. References are also provided for more comprehensive recent reviews.Limitations:The mini-symposium was an opportunity for providing a brief update and overview of neuro-Behçet’s disease and to exchange ideas and experience among neurologists. As such, it was found to be helpful, but also limited in scope. This resultant article refers to comprehensive reviews on the topic but is not in itself a comprehensive systematic review.Conclusions:Neuro-Bechet’s disease comprises largely two forms, parenchymal and a non-parenchymal. These manifestations seldom overlap in the same individual and may reflect different pathogenetic mechanisms. The principles of treatment largely follow the principles of treating Bechet’s disease in general, with the mainstay being corticosteroids for exacerbations and immunosuppressive treatments for prevention of exacerbations. One notable exception is cyclosporine, which is typically avoided in neuro-Bechet’s disease. Anti-tumour necrosis factor biologicals play an increasing role in treatment. Distinguishing neuro-Behçet’s disease from other neuroinflammatory conditions, such as multiple sclerosis, is essential for both management and prognostic reasons.

Sign in / Sign up

Export Citation Format

Share Document